Examination concerning dosage of dexamethasone when Fosaprepitant and Palonosetron are used together for nausea and vomiting induced chemotherapy for head and neck cancer.

Examination concerning dosage of dexamethasone when Fosaprepitant and Palonosetron are used together for nausea and vomiting induced chemotherapy for head and neck cancer. - Examination concerning dosage of dexamethasone when Fosaprepitant and Palonosetron are used together for nausea and vomiting.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008080

Enrollment

Registered

2012-06-01

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer

Interventions

Fosaprepitant 150mg, iv (Day 1) Palonosetron 0. 75mg, iv (Day 1) Dexamethasone 9.9 mg, iv (Day 1) Dexamethasone 6.6 mg, iv (Days 2-4) Fosaprepitant 150mg, iv (Day 1) Palonosetron 0. 75mg, iv (Da

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (a) From 20 or more to 75 years old or less at time of registration. (b) Patients who receive the chemotherapy by two courses involving cisplatin as first line. (c) ECOG PS of patients is 0-2. (d) Patients will provide written informed consent.

Exclusion criteria

Exclusion criteria: (a) Vomiting prior to chemotherapy within 24hours (b) They have the factor (tumor of the brain, street trouble of the gut, ulcus pepticum of briskness, and cerebral metastasis, etc.) that nausea and vomiting are caused besides the cancer chemotherapy (c) They have an associated symptom (ex infectious disease) patient who cannot administer dexamethasone. (d) judged by the investigator to be inappropriate for this study (e) pimozide is being administered.

Design outcomes

Primary

Measure	Time frame
Complete response rate of vomiting within 120hours from cisplatin administration	—

Secondary

Measure	Time frame
(a)Complete response rate of vomiting within 24hours,and 24-120 hours from cisplatin administration. (b)Level of nausea (c)Level of anorexia (d)The proportion of patients receiving rescue medication. (e)Evaluation of nausea and vomiting of each course on 10 point scale. (f)adverse event	—

Countries

Japan

Contacts

Public ContactTsutomu Ueda

Hiroshima University Hospital Department of Otorhinolaryngology, Head and Neck Surgery

uedatsu@hiroshima-u.ac.jp082-257-5252

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026